Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CORT 
Corcept Therapeutics Incorporated (CORT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: CORT (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $135.25
1 Year Target Price $135.25
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 19.74% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.74B USD | Price to earnings Ratio 95.38 | 1Y Target Price 135.25 |
Price to earnings Ratio 95.38 | 1Y Target Price 135.25 | ||
Volume (30-day avg) 4 | Beta 0.2 | 52 Weeks Range 49.00 - 117.33 | Updated Date 12/8/2025 |
52 Weeks Range 49.00 - 117.33 | Updated Date 12/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.32% | Operating Margin (TTM) 4.92% |
Management Effectiveness
Return on Assets (TTM) 5.1% | Return on Equity (TTM) 16.7% |
Valuation
Trailing PE 95.38 | Forward PE 26.32 | Enterprise Value 8313193246 | Price to Sales(TTM) 11.8 |
Enterprise Value 8313193246 | Price to Sales(TTM) 11.8 | ||
Enterprise Value to Revenue 11.66 | Enterprise Value to EBITDA 128.14 | Shares Outstanding 105188217 | Shares Floating 87028523 |
Shares Outstanding 105188217 | Shares Floating 87028523 | ||
Percent Insiders 11.57 | Percent Institutions 75.48 |
Upturn AI SWOT
Corcept Therapeutics Incorporated
Company Overview
History and Background
Corcept Therapeutics Incorporated was founded in 1991. The company is a pharmaceutical company focused on the discovery, development, and commercialization of therapeutics for the treatment of severe metabolic, endocrine, and oncologic disorders. A significant milestone was the development and FDA approval of Korlymu00ae (mifepristone) for the treatment of hypercortisolism. Corcept has evolved from a research-focused entity to a commercial-stage biopharmaceutical company with a proprietary platform for identifying novel applications of steroid receptor modulators.
Core Business Areas
- Endogenous Cushing's Syndrome: Corcept's primary focus is on developing and commercializing therapies for Cushing's syndrome, a rare endocrine disorder caused by prolonged exposure to excessive cortisol. This includes its flagship product, Korlymu00ae.
- Oncology: Corcept is exploring the potential of its proprietary compounds in treating various cancers, particularly those that are driven by or resistant to glucocorticoids. This involves ongoing clinical trials in different cancer types.
- Metabolic and Endocrine Disorders: Beyond Cushing's syndrome, Corcept investigates its compounds for other metabolic and endocrine conditions where steroid hormone pathways play a significant role.
Leadership and Structure
Corcept Therapeutics is led by a seasoned management team with expertise in drug development, commercialization, and finance. The company operates with a matrix structure, aligning research and development, clinical operations, commercial, and corporate functions to advance its pipeline and commercialize its products.
Top Products and Market Share
Key Offerings
- Product Name 1: Korlymu00ae (mifepristone). Korlymu00ae is the first FDA-approved medication for the treatment of hypercortisolism in adult patients with endogenous Cushing's syndrome who are not surgical candidates or for whom surgery has failed. Market share data is proprietary, but it is the sole approved therapy in its niche. Competitors are primarily off-label uses of other drugs and supportive care. Revenue for 2023 was approximately $127 million.
- Product Name 2: Relacoribant (CORT125134). This is an investigational selective cortisol receptor modulator in Phase 2 trials for treating solid tumors, particularly those that are hormone-driven or exhibit glucocorticoid resistance. No specific market share data is available as it is investigational. Competitors include various chemotherapy agents and targeted therapies depending on the cancer type.
- Product Name 3: Corcept's proprietary pipeline of other novel selective cortisol receptor modulators (SCRM). These are in various stages of preclinical and clinical development for oncology and other endocrine disorders. No market share data is applicable.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industry is highly competitive, characterized by extensive research and development, stringent regulatory oversight, and significant capital investment. The rare disease and oncology sectors, where Corcept primarily operates, are particularly dynamic, with increasing demand for novel and effective treatments. The market for treatments for endocrine disorders like Cushing's syndrome is relatively small but unmet.
Positioning
Corcept Therapeutics is positioned as a leader in the niche field of selective cortisol receptor modulation. Its proprietary platform and early-mover advantage with Korlymu00ae provide a competitive edge. The company leverages its deep understanding of steroid hormone biology to develop therapies for conditions with significant unmet medical needs. Its competitive advantage lies in its specialized scientific expertise and its focus on a differentiated therapeutic approach.
Total Addressable Market (TAM)
The TAM for endogenous Cushing's syndrome is estimated to be in the hundreds of millions of dollars, with a significant portion currently untreated or inadequately treated. For oncology indications, the TAM is in the billions of dollars, depending on the specific cancer types targeted. Corcept is positioned to capture a significant share of the niche Cushing's syndrome market with Korlymu00ae and aims to establish a strong presence in oncology with its pipeline candidates.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for developing selective cortisol receptor modulators.
- First-mover advantage and FDA approval for Korlymu00ae in Cushing's syndrome.
- Experienced management team with a strong track record.
- Deep scientific expertise in steroid hormone biology.
- Growing pipeline of promising investigational compounds.
Weaknesses
- Limited product portfolio, heavily reliant on Korlymu00ae.
- Challenges in patient identification and diagnosis for rare diseases.
- High R&D costs associated with drug development.
- Dependence on clinical trial success and regulatory approvals.
Opportunities
- Expansion of Korlymu00ae indications and patient population.
- Successful development and commercialization of pipeline candidates in oncology.
- Partnerships and collaborations for further pipeline advancement.
- Increasing awareness and diagnosis of rare endocrine disorders.
- Potential for new applications of cortisol receptor modulation in other diseases.
Threats
- Competition from other pharmaceutical companies developing similar therapies.
- Potential for adverse events or safety concerns with its products.
- Changes in regulatory landscape and reimbursement policies.
- Patent expirations and generic competition in the future.
- Failure of pipeline candidates in clinical trials.
Competitors and Market Share
Key Competitors
- Novo Nordisk A/S (NVO)
- AstraZeneca PLC (AZN)
- Merck & Co., Inc. (MRK)
Competitive Landscape
Corcept's advantages lie in its specialized focus on cortisol receptor modulation and its established presence in the Cushing's syndrome market. However, larger pharmaceutical companies like Novo Nordisk, AstraZeneca, and Merck have broader portfolios, extensive R&D capabilities, and larger commercial infrastructure, posing a competitive challenge, especially in the broader oncology space. Corcept's success hinges on its ability to differentiate its therapies and secure market access for its niche products.
Growth Trajectory and Initiatives
Historical Growth: Corcept has experienced significant growth since the approval and commercialization of Korlymu00ae. Revenue has steadily increased year over year, and the company has expanded its pipeline with promising candidates entering clinical trials.
Future Projections: Analyst projections suggest continued revenue growth for Corcept, driven by increasing adoption of Korlymu00ae and the potential approval of its pipeline candidates, particularly in oncology. The company is expected to remain a key player in the niche endocrine disorder market and aims to expand its footprint in oncology.
Recent Initiatives: Recent initiatives include the advancement of Relacoribant (CORT125134) in Phase 2 trials for various solid tumors, ongoing research into new indications for mifepristone, and the development of novel SCRMs for unmet medical needs in oncology and metabolic disorders.
Summary
Corcept Therapeutics is a specialized biopharmaceutical company with a strong position in rare endocrine disorders, anchored by its product Korlymu00ae. The company exhibits consistent revenue growth and improving profitability. Its primary strengths lie in its proprietary technology and scientific expertise. However, it faces risks related to pipeline development success, competition, and reliance on a limited product base. Continued investment in R&D and successful clinical outcomes are crucial for its sustained growth and market expansion, particularly in the competitive oncology landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Reports (SEC Filings)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (General Industry Data)
Disclaimers:
This JSON output is generated based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Market share data and projections are estimates and may not be entirely accurate. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corcept Therapeutics Incorporated
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2004-04-14 | Co-Founder, President, CEO & Director Dr. Joseph K. Belanoff M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 500 | Website https://www.corcept.com |
Full time employees 500 | Website https://www.corcept.com | ||
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.